Overview
Wolverine (BPC + TB) plus GHK-Cu.
Adds skin, hair, and connective-tissue support to the basic healing stack.
What It Does
Three-peptide regenerative blend: GHK-Cu (4,000+ repair genes) + TB-500 (systemic repair) + BPC-157 (healing).
Pre-mixed convenience.
TB-500 upregulates thymosin β4 for systemic repair.
BPC-157 drives local angiogenesis.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 70 mg | + 5 mL | GHK-Cu 10 mg/mL |
Interactive tool
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Calculated concentration—Enter both values above.
Optional conversion
Enter a target amount you already have and select the syringe capacity.
Calculated draw—Enter concentration inputs and a target amount.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Protocol
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Week 1 | Daily | 1 mg | Loading. 1 mg GHK-Cu + 0.2 mg BPC-157 + 0.2 mg TB-500 per dose. |
| Week 2 | Daily | 1.5 mg | Ramp. 1.5 mg GHK-Cu + 0.3 mg BPC + 0.3 mg TB per dose. |
| Weeks 3–8 | Daily | 2 mg | Working dose. 2 mg GHK-Cu + 0.4 mg BPC + 0.4 mg TB per dose. |
| Aggressive | Daily (AM + PM split) | 3–4 mg | Bump here ONLY if 2+ weeks at 2 mg with zero injection-site issues AND a specific high-demand goal. Start at 3 mg (= 0.6 above 3 mg/day; cost roughly doubles. |
| Off | 4 weeks | – | Mandatory copper-accumulation washout. Do not skip, especially after an Aggressive phase. |
Cycle & Timing
8 weeks on / 4 weeks off, matches GHK-Cu copper-accumulation limits.
Timing
Daily SubQ, anytime; same as the Wolverine base.
Population Considerations
Unisex (GHK-Cu + BPC-157 + TB-500 repair / skin), same protocol for men and women, no cycle effect. Avoid in pregnancy.
Handling & Stacking
Injection site
SubQ near target tissue. Rotate.
Storage
- Freeze-dried: -4°F.
- Reconstituted: 36–46°F, protect from light.
- Best used within about 2–4 weeks, kept cold and dark (structure-based estimate, no published data); copper oxidizes with no visible colour change, so use it sooner rather than later.
Side effects
Usually minimal. Injection-site irritation occasionally.
What to expect
- Broad tissue repair, skin quality improvement, and anti-inflammatory effects build over the 8-week cycle.
- 4-week washout follows.
- Supply math 70mg → 2 vials (8-wk @ 2 mg × 7/wk).
- 70 mg vial covers ~half of an 8-week cycle at 2 mg/day; reconstituted shelf life ~28 days.
- Aggressive 3–4 mg/day depletes the vial faster but stays inside the discard window.
Pairs well with
CJC-1295 No DAC + Ipamorelin (systemic GH + local repair); Thymosin Alpha-1 (immune support); Epithalon (longevity / collagen complement)
Avoid
NSAIDs during a repair cycle (ibuprofen/Advil/Aleve slow healing on their own; use Tylenol for pain). High-dose vitamin C same session (copper oxidation)
Safety & Patient Education
Contraindications
- Active or suspected malignancy.
- TB-500 is angiogenic systemically; BPC-157 drives angiogenesis locally via VEGF; copper is an angiogenesis cofactor, so all three point the same way.
- Theoretical, there’s no human evidence they cause cancer, but they can’t tell healthy tissue from a tumour you don’t know about.
- Screen age-appropriately before a long run; stop for any new lump.
- Wilson’s disease, copper dysregulation, copper allergy (GHK-Cu component) Active bleeding or recent hemorrhagic stroke (TB-500 vascular effects) Pregnancy, lactation
Warnings
- Combines three compounds with no human RCT data on the blend itself.
- Quality varies by compounder; request COA listing each component’s purity.
- GHK-Cu: extended continuous use can cause copper accumulation, the 6-week off period is critical.
- BPC-157: FDA Category 2 in 2023; compounding from bulk substances is restricted.
- TB-500: no published human efficacy trials; theoretical malignancy risk via angiogenesis.
- BPC-157 & TB-500 were both RECOMMENDED for the 503A bulks list by PCAC (8–6 each, Jul 2026; advisory, non-binding).
Drug interactions
NSAIDs: don’t blunt the blend (a myth); skip during a repair cycle, NSAIDs slow healing themselves High-dose vitamin C same session: theoretical copper-ascorbate redox interaction with GHK-Cu Anticoagulants (warfarin, DOACs): caution with TB-500 vascular effects
Labs
- Compound-specific: hsCRP (baseline + end) Serum copper and ceruloplasmin if cycles extend beyond 6 weeks (GHK-Cu accumulation) Out of range?
- Rising serum copper / ceruloplasmin = copper is accumulating → pause and re-dose lower.
Stop criteria
New mass or unexpected tissue growth at any injection site Skin discoloration, neurological symptoms (copper toxicity from GHK-Cu) Persistent injection-site reactions beyond 7 days
Patient education
- Three-peptide blend: any single-component contraindication applies to the whole blend.
- Cycle discipline matters more than dose: 6 weeks on / 6 weeks off is the canonical pattern.
- Inject SubQ near target tissue.
- Rotate sites to reduce GHK-Cu sting.
References
researchdosing · peptidedosages · PubMed · thepeptidereport · peptides.id
